Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers

Cancer chemotherapeutic drugs exert cytotoxic effects by modulating intracellular reactive oxygen species (ROS) levels. However, whether ROS modulates the efficacy of targeted therapeutics remains poorly understood. Previously, we reported that upregulation of the anti-apoptotic protein, BCL-XL, by...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer letters 2021-01, Vol.497 (C), p.123-136
Hauptverfasser:	Oh, Yumi, Jung, Hae Rim, Min, Seoyeon, Kang, Jinjoo, Jang, Dongjun, Shin, Seungjae, Kim, Jiwon, Lee, Sang Eun, Sung, Chang Ohk, Lee, Won-Suk, Lee, Charles, Jeong, Eui Man, Cho, Sung-Yup
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Methoxyestradiol ABT-263 Antioxidant system Colorectal cancer KRAS mutation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!